SECOND OPINION: PHRMA’S LAST-DITCH ATTEMPT TO DERAIL SOLUTIONS TO LOWER DRUG PRICES REHASHES DEBUNKED ARGUMENTS

08-5-2022 Blog Posts

Pharmaceutical Industry Attempts to Intimidate Lawmakers and Keep Prices High by Re-Upping False Claims, Blame Game and Discredited Innovation Rhetoric On Thursday, the Pharmaceutical Research and Manufacturers of America (PhRMA) sent a letter from the organization’s board of directors in a last-minute bid to intimidate lawmakers into voting against drug pricing solutions included in the […]

ICYMI: CIVICASCRIPT BRINGS FIRST GENERIC DRUG TO MARKET TO PROVIDE MORE AFFORDABLE ALTERNATIVE TO HIGH-PRICED BIG PHARMA PRODUCTS

08-3-2022 Blog Posts

Private Sector and Non-Profit Partners Introduce Cancer Treatment That Can Save Patients Thousands of Dollars Per Month In case you missed it, CivicaScript, a collaboration between non-profit drug manufacturer Civica Rx, the Blue Cross Blue Shield Association (BCBSA) and 18 Blue Cross and Blue Shield (BCBS) companies, has manufactured and brought to market its first generic drug […]

BIG PHARMA EARNINGS WATCH: PFIZER, MERCK, BRISTOL MYERS SQUIBB, GLAXOSMITHKLINE AND SANOFI

07-29-2022 Blog Posts

Big Pharma Giants All Top Analysts’ Expectations as Pharmaceutical Industry Continues to Price-Gouge and Fight Market-Based Solutions to Lower Drug Prices In another round of blockbuster earnings for the second quarter of the year, Big Pharma giants Pfizer, Merck, Bristol Myers Squibb, GlaxoSmithKline and Sanofi all reported stellar earnings that topped Wall Street analysts’ expectations. […]

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON, ROCHE, NOVARTIS

07-22-2022 Blog Posts

Big Pharma Kicks Off Q2 Earnings Calls After More than 100 Price Hikes to Start July This week, Roche, Novartis, and Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the second quarter of 2022. After drug companies raised prices on more than 100 brand-name pharmaceuticals in the first week […]

ICYMI: USPTO, FDA ANNOUNCE PLAN TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE

07-19-2022 Blog Posts

Joint Effort Aims to Curb Anti-Competitive Tactics Used by Brand Name Drug Companies to Block More Affordable Alternatives In case you missed it, the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) recently announced a joint effort to crack down on Big Pharma’s anti-competitive gamesmanship of the patent system. The […]

SECOND OPINION: BIG PHARMA’S PRICE HIKES HAVE LONG OUTPACED INFLATION

07-11-2022 Blog Posts

PhRMA Ads Falsely Claim the Industry’s Egregious Pricing Practices Don’t Drive Prescription Drug Inflation Amid unprecedented momentum to hold Big Pharma accountable and lower prescription drug prices, the pharmaceutical industry is once again trying to deflect blame with false rhetoric meant to evade responsibility for brand name drug companies’ egregious practices. New advertising from the […]

BIG PHARMA WATCH: ABBVIE UTILIZED LOOPHOLES TO AVOID PAYING BILLIONS IN U.S. TAXES & FURTHER MAXIMIZE PROFITS WHILE HIKING PRICES

07-8-2022 Blog Posts

Committee Report Shows How Brand Name Drug Company Further Juiced Profits on Blockbuster Drug Already Known as a Case Study for Big Pharma’s Greed In case you missed it, on Thursday the U.S. Senate Committee on Finance released an interim report examining strategies employed by Big Pharma company AbbVie to avoid paying taxes on profits […]

DOSE OF REALITY: PATENT HEARINGS OFFER OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE FOR ANTI-COMPETITIVE PRACTICES

06-22-2022 Blog Posts

Lawmakers Can Highlight Tactics Designed to Block More Affordable Alternatives from the Market — Add to Momentum for Market-Based Solutions  In Washington this week, Congress will hold a pair of hearings on the patent system, offering an opportunity for lawmakers to detail Big Pharma’s anti-competitive practices that drive higher prescription drug prices and add to […]

SECOND OPINION: PHRMA REDUXES DEBUNKED BLAME GAME RHETORIC IN NEW AD CAMPAIGN

06-17-2022 Blog Posts

Big Pharma Trots Out Tired, Dishonest Arguments Designed to Evade Accountability, Keep Prices High As lawmakers in Congress continue to weigh market-based solutions to lower prescription drug prices, Big Pharma is once again doubling down on bogus blame game tactics — designed to evade accountability for brand name drug companies’ egregious practices and keep prices […]

THEY SAID IT! ANTITRUST EXPERTS AND OFFICIALS SHINE A LIGHT ON BIG PHARMA’S ANTI-COMPETITIVE PLAYBOOK

06-16-2022 Blog Posts

Federal Trade Commission Workshop Highlights How Brand Name Drug Companies Game the System to Keep Prices High — Demonstrating the Urgency for Congress to Act This week, the Federal Trade Commission and U.S. Department of Justice Antitrust Division hosted a two-day virtual workshop on enforcing antitrust laws in the pharmaceutical industry. The workshop brought together […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.